July, 2025

article thumbnail

In seconds, AI builds proteins to battle cancer and antibiotic resistance

Science Daily: Pharmacology News

Artificial intelligence is now designing custom proteins in seconds—a process that once took years—paving the way for cures to diseases like cancer and antibiotic-resistant infections. Australian scientists have joined this biomedical frontier by creating bacteria-killing proteins with AI. Their new platform, built by a team of biologists and computer scientists, is part of a global movement to democratize and accelerate protein design for medical breakthroughs.

article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

State-of-the-art covalent virtual screening with AlphaFold3

Covalent Modifiers

Yoav Shamir, Nir London bioRxiv 2025.03.19.642201 doi: [link] Recent years have seen an explosion in the prominence of covalent inhibitors as research and therapeutic tools. However, a lag in application of computational methods for covalent docking slows progress in this field. AI models such as AlphaFold3 have shown accuracy in ligand pose prediction but were never assessed for virtual screening.

article thumbnail

AI and Digital Trends Marketing and IT Leaders Need to Know

Perficient: Drug Development

In Adobe’s 2025 AI and Digital Trends report, one message rings loud and clear: the convergence of marketing and IT is essential to digital success. As AI becomes increasingly embedded in customer experience strategies, marketing and IT leaders must collaborate closely to unlock its full potential. The Rise of Agentic AI One of the most transformative ideas in the report is the rise of agentic AI, autonomous systems that collaborate across platforms to deliver hyper-personalized, real-time exper

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Prime editing treats childhood brain disease in mice

Broad Institute

Prime editing treats childhood brain disease in mice By Corie Lok July 21, 2025 Breadcrumb Home Prime editing treats childhood brain disease in mice Scientists use a precise form of gene editing called prime editing to correct the most common genetic mutations that cause alternating hemiplegia of childhood, a rare and severe neurological disorder that begins in infancy.

article thumbnail

Multifaceted In Silico Screening Strategies Identifies Potent Inhibitors Facilitating Inhibition of ZNF726 Activity in Breast Cancer

Chemical Biology and Drug Design

Zoledronic acid was identified as a lead hit targeting ZNF726 activity, inhibiting its proliferative effects on breast cancer cells. Zoledronic acid inhibits cellular cholesterol level through the inhibition of ZNF726 activity in breast cancer cells. Nine phytochemicals were identified from docking studies that might be used as potential therapeutics for targeting ZNF726 activity.

More Trending

article thumbnail

Protein degraders: chasing undruggable targets

BioPharma Drive: Drug Pricing

Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.

article thumbnail

Future-proofing drug development with GenAI

Drug Target Review

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. However, R&D stakeholders are learning that GenAI underpinned by domain expertise also enables deep dives into the broader long-term potential of their investigational asset(s) as early as the preclinical phase.

article thumbnail

Research progress on covalent inhibitors targeting alkaline amino acids

Covalent Modifiers

Bing Zhao, Sha Xu, Shiqing Zhou, Xiangru Jiang, Ailin Jiang, Hongrui Lei, Xin Zhai Bioorganic Chemistry, 163, 2025, 108800, [link] [link] the past two decades, covalent inhibitors have undergone a remarkable resurgence in drug discovery. Currently, targeting non-catalytic cysteine residues with acrylamide and other α,β-unsaturated carbonyl compounds is a predominate strategy, especially in the protein kinase field.

article thumbnail

Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets

Broad Institute

Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets By Leah Eisenstadt July 24, 2025 Breadcrumb Home Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets Combining powerful imaging, perturbational screening, and machine learning, researchers uncover new human host factors that alter Ebola’s ability to infect.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Computationally Guided Structural Modification of Centaureidin: A Novel Approach for Enhancing Antioxidant and Antitumor Activities for Drug Development

Chemical Biology and Drug Design

Computationally guided modifications of centaureidin led to the development of CA4, demonstrating enhanced antioxidant and antitumor activities. Molecular docking and in vitro assays confirm improved binding affinity and cytotoxicity, highlighting CA4's potential as a promising drug candidate for cancer therapy. ABSTRACT The development of novel therapeutic drugs with enhanced efficacy has gained significant attention in recent years.

article thumbnail

Researchers grow 400+ brain cell types—a leap for Alzheimer’s and Parkinson’s research

Science Daily: Pharmacology News

Scientists at ETH Zurich have broken new ground by generating over 400 types of nerve cells from stem cells in the lab, far surpassing previous efforts that produced only a few dozen. By systematically experimenting with combinations of morphogens and gene regulators, the researchers replicated the vast diversity of neurons found in the human brain.

article thumbnail

Lilly gets FDA OK of modified dosing for Alzheimer’s drug

BioPharma Drive: Drug Pricing

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to prescribe Lilly’s amyloid-busting drug.

article thumbnail

The AI model that is changing clinical trial design

Drug Target Review

Clinical trials are expensive, slow and often limited by outdated design constraints. Placebo arms, in particular, create ethical and logistical hurdles, especially in areas like rare disease and oncology. Digital twins offer a way forward. They offer patient-specific outcome predictions, generated using machine learning models trained on real historical clinical data.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Rational Design of CDK12/13 and BRD4 Molecular Glue Degraders

Covalent Modifiers

Nathanael Schiander Gray , Zhe Zhuang , Woong Sub Byun , Zuzanna Kozicka , Katherine Donovan , Brendan Dwyer , Abby Thornhill , Hannah Jones , Zixuan Jiang , Xijun Zhu , Eric Fischer , Nicolas Thomä , Angew. Chem. Int. Ed. 2025 , e202508427. [link] Targeted protein degradation (TPD) is an emerging therapeutic approach for the selective elimination of disease-related proteins.

article thumbnail

What is the Model Context Protocol?

Perficient: Drug Development

You can think of the Model Context Protocol (MCP) as USB for large language models (LLMs), allowing an LLM to interact with a variety of external systems in a uniform manner. It was developed by Anthropic to solve the fundamental problem of getting a text generator (LLM) to perform real-world actions on a user’s behalf. Solving the M x N Problem With a growing number of powerful LLMs (M) and a vast universe of applications and APIs (N) for them to interact with, one would need to develop M

article thumbnail

Collaborative Drug Discovery and deepmirror Announce Collaboration for Humanitarian and Commercial Drug Discovery

Collaborative Drug

BURLINGAME, Calif. — July 8, 2025. Collaborative Drug Discovery (CDD) , the leading provider of data management solutions for the pharmaceutical and biotechnology industries, and deepmirror , the AI drug design platform that empowers chemists to focus on more promising drug molecules, today announced a strategic partnership integrating deepmirror with CDD Vault to enhance drug discovery.

article thumbnail

Ultrafast 12-minute MRI maps brain chemistry to spot disease before symptoms

Science Daily: Pharmacology News

Illinois engineers fused ultrafast imaging with smart algorithms to peek at living brain chemistry, turning routine MRIs into metabolic microscopes. The system distinguishes healthy regions, grades tumors, and forecasts MS flare-ups long before structural MRI can. Precision-medicine neurology just moved closer to reality.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Synthesis and Bioactivity Evaluation of Novel Sulfonamide‐1,2,3‐Triazole Hybrids: In Vitro and In Silico Studies

Chemical Biology and Drug Design

Novel 1,2,3-triazole derivatives incorporating a 4-iodosulfonamide moiety were synthesized. Their antioxidant properties were evaluated using DPPH, ABTS, and CUPRAC methods. The inhibitory activity of the compounds against cholinesterases (AChE and BuChE) was investigated. An investigation of their anticancer properties against Caco-2 and PC3 cancer cell lines was also conducted.

article thumbnail

The future of CNS drug development: signs of real progress

Drug Target Review

Hundreds of life-altering conditions attack the central nervous system (CNS). Disorders such as Alzheimer’s disease , primary glioblastoma and amyotrophic lateral sclerosis (ALS) all affect the CNS and are considered fatal, while more common conditions, including depression , strokes and epilepsy , require long-term treatments. According to the World Health Organization (WHO) , neurological conditions are now the number one cause of ill health and disability across the globe, 1 highlighting the

article thumbnail

Why Mallory Freeberg is creating a perturbation catalogue

The Open Targets Blog

How can you work out the function of a particular gene or protein across different cell types and functions? If you perturb it—modify it and observe the consequences—you can start to unravel what its biological role might be, and determine whether the effects are unique to one cell type or whether they propagate across different cell contexts.

article thumbnail

Transforming Cancer Therapy: Insights from 2025 H1 FDA Approvals and Preclinical Drug Discovery

Crown Bioscience

Oncology drug approvals in H1 2025 In the first half of 2025, the FDA’s Center for Drug Evaluation and Research (CDER) approved a total of 16 novel drugs , with half of these drugs related to the treatment of cancer. Both the novel and supplemental oncology approvals reflected recent developmental innovations, including an increased focus on targeted, immunologically driven, and personalized oncology therapies, targeting a broad range of cancers.

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Recap Of The Collaborative Drug Discovery's Inaugural Canadian User Group Meeting

Collaborative Drug

The 2025 CDD User Group Meeting (UGM) Canada brought together researchers, industry experts, and thought leaders to discuss the latest advancements in drug discovery, data management, and collaborative research.

article thumbnail

Millipedes make ants dizzy — and might soon treat human pain

Science Daily: Pharmacology News

Millipedes, often dismissed as creepy crawlies, may hold the secret to future painkillers and neurological drugs. Researchers at Virginia Tech discovered unique alkaloid compounds in the defensive secretions of a native millipede species. These complex molecules, which cause disorientation in ants, interact with human neuroreceptors linked to pain and cognition.

article thumbnail

The structure of KRASG12C bound to divarasib highlights features of potent switch-II pocket engagement

Covalent Modifiers

Fernando, M. C., Craven, G. B., & Shokat, K. M. Small GTPases, 2024 15(1), 1–7. [link] KRAS is the most frequently mutated oncogene in human cancer. In multiple types of cancer, a missense mutation at codon 12 substitutes a glycine for a cysteine, causing hyperactivation of the GTPase and enhanced MAPK signalling. Recent drug discovery efforts culminating from work during the past decade have resulted in two FDA-approved inhibitors, sotorasib and adagrasib, which target the KRASG12C mutant a

article thumbnail

Designing antibodies to think before they bind

Drug Target Review

Antibody therapies have transformed cancer treatment, yet their limits are becoming increasingly clear – particularly when tumours evolve, evade immune detection or develop resistance to existing drugs. For Dr Jhong-Jhe ‘JJ’ You, Vice President of Antibody Discovery at AP Biosciences, these challenges are not setbacks. They are starting points. With a background in neurobiology, immuno-oncology and bispecific engineering, JJ now leads the development of antibody candidates designed to go further

article thumbnail

PALAZESTRANT

New Drug Approvals

PALAZESTRANT CAS 2092925-89-6 OP-1250, VU35KM56Q4 449.6 g/mol, C 28 H 36 FN 3 O (1 R ,3 R )-2-(2-fluoro-2-methylpropyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-{4-[(1-propylazetidin-3- yl)oxy]phenyl}-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Palazestrant (OP-1250) is an investigationa

article thumbnail

Key assays and analytical techniques for the development of antibody drug conjugates

Crown Bioscience

Highly targeted antibody-drug conjugates (ADCs) combine an antibody with a cytotoxic payload, covalently attached via a chemical linker. These “ biological missiles ” represent an exciting new advance in anti-cancer therapies and are one of the fastest-growing segments in oncology drug development. Due to their complex make-up and multiple components, analysis of their chemistry and functionality is challenging, requiring advanced assays and techniques for effective study and characterization.

article thumbnail

A Visual Guide to Gene Delivery

Codon

A gene is the essential hereditary unit that passes traits from parents to offspring; a segment of DNA containing instructions for making a specific protein or molecule that performs a particular function in your body. And yet, despite being fundamental to our flourishing, genes can be broken. Researchers have identified nearly 10,000 monogenic diseases , or conditions caused by errors in a single gene.

article thumbnail

Cracking the carbene code: A 100x faster path to life-saving drugs

Science Daily: Pharmacology News

Using a clever combo of iron and radical chemistry, scientists have unlocked a safer, faster way to create carbenes molecular powerhouses key to modern medicine and materials. It s 100x more efficient than previous methods.

article thumbnail

Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding

BioPharma Drive: Drug Pricing

The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" and "potentiator" medicines for the kidney disease.

article thumbnail

Fixing failed drugs: AI solutions for toxicity in drug discovery – part 2

Drug Target Review

In Part 2 of our conversation with Layla Hosseini-Gerami, Chief Data Science Officer at Ignota Labs , we explore the many forms of toxicity and how AI-powered tools like omics and cell painting are transforming early prediction in pre-clinical research. The conversation revealed important distinctions between different types of toxicity and our current ability to predict them: “For certain types of toxicity like liver and cardio, I think those are quite well understood in terms of the mech